ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer

期刊论文
出版模式：

开放获取
发表日期：

2024年4月10日

查看全文

Antonio Juan-Ribelles,
Francisco Bautista,
Adela Cañete,
Alba Rubio-San-Simón,
Anna Alonso-Saladrigues,
Raquel Hladun,
Susana Rives,
Jose Luís Dapena,
Jose María Fernández,
Álvaro Lassaletta,
Ofelia Cruz,
Gemma Ramírez-Villar,
Jose Luís Fuster,
Cristina Diaz de Heredia,
Miguel García-Ariza,
Eduardo Quiroga,
María del Mar Andrés,
Jaime Verdú-Amorós,
Antonio Molinés,
Blanca Herrero,
Mónica López,
Catalina Márquez,
María Toboso,
Frencisco Lendínez,
Jose Gómez Sirvent,
María Tallón,
Guiomar Rodríguez,
Tomás Acha,
Lucas Moreno,
Ana Fernández-Teijeiro

摘要

Introduction

ECLIM-SEHOP platform was created in 2017. Its main objective is to establish the infrastructure to allow Spanish participation into international academic collaborative clinical trials, observational studies, and registries in pediatric oncology. The aim of this manuscript is to describe the activity conducted by ECLIM-SEHOP since its creation.

Methods

The platform’s database was queried to provide an overview of the studies integrally and partially supported by the organization. Data on trial recruitment and set-up/conduct metrics since its creation until November 2023 were extracted.

Results

ECLIM-SEHOP has supported 47 studies: 29 clinical trials and 18 observational studies/registries that have recruited a total of 5250 patients. Integral support has been given to 25 studies: 16 trials recruiting 584 patients and nine observational studies/registries recruiting 278 patients. The trials include front-line studies for leukemia, lymphoma, brain and solid extracranial tumors, and other key transversal topics such as off-label use of targeted therapies and survivorship. The mean time from regulatory authority submission to first patient recruited was 12.2 months and from first international site open to first Spanish site open was 31.3 months.

Discussion

ECLIM-SEHOP platform has remarkably improved the availability and accessibility of international academic clinical trials and has facilitated the centralization of resources in childhood cancer treatment. Despite the progressive improvement on clinical trial set-up metrics, timings should still be improved. The program has contributed to leveling survival rates in Spain with those of other European countries that presented major differences in the past.